Navigation Links
New Data Supports Significant Economic and Clinical Value of MENOPUR(R) in IVF
Date:6/30/2009

AMSTERDAM, The Netherlands, June 30 /PRNewswire/ --

- "Study Could Have Major Impact on the Decision-Making Process With Respect to Infertility Treatment"

New data from an economic analysis presented today at this year's European Society of Human Reproduction and Embryology (ESHRE) congress showed that, within the parameters of the simulation model used, the in vitro fertilisation (IVF) treatment MENOPUR (highly-purified human menopausal gonatropin or HP-hMG) offered considerable cost-savings over recombinant follicle stimulating hormone (rFSH).[1] The cost-effectiveness of HP-hMG compared with rFSH suggested by this data could make it a more attractive choice for use in infertility treatment within a fixed healthcare budget.

In today's difficult global financial situation, the cost-effectiveness of infertility treatments, such as IVF, is more important than ever. Experiencing fertility problems is deeply distressing and isolating for couples and the cost of treatment is one of many considerations for people seeking treatment. A recent audit of European infertility patient groups showed that infertile couples are calling for clear information on the cost-effectiveness, as well as the efficacy of individual treatments.[2]

HP-hMG and rFSH are two commonly used hormonal therapies belonging to the class of drugs known as gonadotropins that enhance egg production in IVF treatment. HP-hMG, contains both FSH and hCG-driven (human chorionic gonadotropin) LH-activity (luteinizing hormone). In contrast, rFSH is a recombinant product and contains only rFSH.

"Until recently, discussions regarding funding for infertility treatment services have been hindered by a relative paucity of economic studies of the specific treatments," points out study investigator Dr Jaro Wex from PharmArchitecture, UK.

"Our new study compared success rates and value for money of gonadot
'/>"/>

SOURCE Ferring Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. New Study Supports Efficacy of Vagus Nerve Stimulation for Treatment-Resistant Depression
2. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
3. Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer
4. Cost-Effectiveness Study Supports Use of EUFLEXXA(TM) by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis
5. New Data from the Framingham Heart Study Supports PAT Technology to Diagnose Early Cardiovascular Disease
6. Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
7. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
8. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
9. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
10. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
11. New Clinical Data Further Supports Chromium Picolinates Role in Enhancing Brain Activity in Older Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014 /CNW/ - Bedrocan Cannabis Corp., ... independent members to its Board of Directors, enhancing ... of the company, a leading licensed producer of ... Internationally, Bedrocan has 13 years, experience in producing ... seven countries, including Canada. As ...
(Date:8/21/2014)... Aug. 21, 2014   Auxilium Pharmaceuticals, Inc. ... biopharmaceutical company, today announced positive results from a ... histolyticum (or CCH) for the treatment of edematous ... the Phase 2a trial, all three doses of ... showed an improvement in the appearance of cellulite ...
(Date:8/20/2014)... , Aug. 20, 2014  The National Association ... latest results achieved by the real-time, pseudoephedrine (PSE) ... National Precursor Log Exchange (NPLEx), automatically blocks unlawful ... down methamphetamine offenders and make arrests. Data released ... Missouri blocked the sale of more ...
Breaking Medicine Technology:Senior Life Sciences Executives Join Bedrocan as Independent Directors 2Senior Life Sciences Executives Join Bedrocan as Independent Directors 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 2Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 4Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 5Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 6Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 7Missouri's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
... ZURICH, July 16 An innovative ... fibrosis patients has received a second,orphan drug designation ... designation was,granted. The recent designation relates to Burkholderia ... fibrosis patients. For Axentis,Pharma AG of Zurich, Switzerland, ...
... , , , ... are a source of worry for many who fear Alzheimer,s ... July 16 issue of the New England Journal of Medicine suggests that ... to have memory declines in their mid-50s, far earlier than previously thought. ...
Cached Medicine Technology:Cystic Fibrosis - Liposomal Tobramycin Receives Second Orphan Drug Designation Within Weeks 2Cystic Fibrosis - Liposomal Tobramycin Receives Second Orphan Drug Designation Within Weeks 3Mayo Clinic Study Finds Earliest Evidence of Memory Decline in Middle-Aged People at Genetic Risk for Alzheimer's Disease 2Mayo Clinic Study Finds Earliest Evidence of Memory Decline in Middle-Aged People at Genetic Risk for Alzheimer's Disease 3Mayo Clinic Study Finds Earliest Evidence of Memory Decline in Middle-Aged People at Genetic Risk for Alzheimer's Disease 4Mayo Clinic Study Finds Earliest Evidence of Memory Decline in Middle-Aged People at Genetic Risk for Alzheimer's Disease 5Mayo Clinic Study Finds Earliest Evidence of Memory Decline in Middle-Aged People at Genetic Risk for Alzheimer's Disease 6Mayo Clinic Study Finds Earliest Evidence of Memory Decline in Middle-Aged People at Genetic Risk for Alzheimer's Disease 7
(Date:8/21/2014)... 21, 2014 When children go back to ... can cause them to become sick and risk missing school. ... to help them fight these germs to ensure a successful ... do just that with its XFactor program. , The XFactor ... chewable multi-vitamins. Children ages 4 and up can receive 30-day ...
(Date:8/21/2014)... 2014 Young girls with an intense, red, itchy ... increased risk of developing urinary tract infections (UTIs), according ... The treatment may be as simple as better hygiene ... swimming pools. , "Vulvitis is a common condition affecting ... Steve J. Hodges, M.D., associate professor of urology at ...
(Date:8/21/2014)... 21, 2014 Greater awareness among parents ... babies before they are full term has decreased the ... of the country, early elective deliveries (EEDs) still occur ... years, EED is defined as delivery before 39 weeks ... neonatal morbidity and mortality, and offers no benefit to ...
(Date:8/21/2014)... Steven Reinberg HealthDay ... An experimental drug shows promise in treating respiratory syncytial virus ... "We are finally making major progress in being able ... cause of serious viral pneumonia, second only to influenza virus," ... at the University of Tennessee College of Medicine in Memphis. ...
(Date:8/21/2014)... Indiana (PRWEB) August 21, 2014 ... employee benefits advisory organization, is pleased to announce ... Based in Knoxville, Tennessee, Trinity Benefit Advisors ... close, long-term relationships with their clients. Their consultative ... planning and objective setting, implementation, and monitoring. Their ...
Breaking Medicine News(10 mins):Health News:MedX Pharmacy Helps with Back to School Preparation 2Health News:Researchers identify potential risk factors for urinary tract infections in young girls 2Health News:New “Playbook” Aims to Eliminate Early Elective Deliveries in the United States 2Health News:New “Playbook” Aims to Eliminate Early Elective Deliveries in the United States 3Health News:New Drug May Fight Serious Respiratory Virus in Infants 2Health News:New Drug May Fight Serious Respiratory Virus in Infants 3Health News:Trinity Benefit Advisors is the Latest Firm to Join United Benefit Advisors 2Health News:Trinity Benefit Advisors is the Latest Firm to Join United Benefit Advisors 3
... The British Association for Psychopharmacology (BAP) has released fresh ... and addiction in the Journal of Psychopharmacology , ... researched the new, comprehensive guidelines, offering practitioners a detailed ... clinical decisions. The new BAP guidelines target treatment ...
... with intact proteins of the same kind, thereby triggering ... discovered by researchers from the RUB Heart and Diabetes ... Hendrik Milting in an interdisciplinary research project with colleagues ... report in the Journal of Biological Chemistry . ...
... , WEDNESDAY, May 23 (HealthDay News) -- The ... reduced through a multi-pronged approach that includes more training ... to a new German study. Despite legal regulations ... as bed rails and belts still are frequently used ...
... resilient metal wire designed to gather and compress diseased lung ... a subtype of the disease that involves specific, usually isolated ... multicenter international trial conducted in the Netherlands, Germany and France. ... be easily implanted and is designed to take the place ...
... imaging (MRI) provides an indication of a breast tumor,s ... clinical examination, according to a new study published online ... with breast cancer often undergo chemotherapy prior to surgery. ... known as neoadjuvant chemotherapy, are more likely to achieve ...
... Ill. -- Children born with cleft lip, cleft palate ... appearance. Patients can face serious airway, feeding, speech ... challenges, Laura Swibel Rosenthal, MD, of Loyola University Medical ... of Otolaryngologic Clinics of North America . ...
Cached Medicine News:Health News:British experts update addiction treatment guidelines 2Health News:Aggregating instead of stabilizing: New insights into the mechanisms of heart disease 2Health News:Study Offers Ways to Decrease Use of Restraints at Nursing Homes 2Health News:Tiny implanted coil improves lung function in patients with severe emphysema 2Health News:Tiny implanted coil improves lung function in patients with severe emphysema 3Health News:Breast MRI helps predict chemotherapy's effectiveness 2Health News:Cleft lip/palate cause much more than cosmetic problems 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: